Zymeworks Announces New Multispecific Antibody Collaboration with Merck; Zymeworks Eligible To Receive Up To $411M In Option Exercise Fees And Clinical Development And Regulatory Approval Milestone Payments And Up To $480M In Commercial Milestone Payments

$MRK $ZYME